Table 2.
Comparing FAP versus AFAP upper gastrointestinal phenotypes
| Characteristics | Total (n = 150) | FAP (n = 79) | AFAP (n = 71) | p-value1 |
|---|---|---|---|---|
| Number duodenal polyps: | ||||
| Median (25th–75th percentile) | 7 (1–18) | 17 (8–33) | 4 (0–7) | < 0.0001* |
| Sum diameter duodenal polyps: | ||||
| Median (25th–75th percentile) | 15.5 (5–43) | 32 (15–75) | 7 (0–15) | < 0.0001* |
| Number with zero duodenal polyps | 27 (18.0%) | 6 (7.6%) | 21 (29.6%) | 0.0005 |
| Spigelman classification: 0 | 27 (18.0%) | 6 (7.6%) | 21 (29.6%) | < 0.0001* |
| I | 19 (12.7%) | 3 (3.8%) | 16 (22.5%) 30 (42.3%) |
|
| II | 81 (54%) | 51 (64.6%) | ||
| III | 22 (14.7%) | 18 (22.8%) | 4 (5.6%) | |
| IV | 1 (0.7%) | 1 (1.3%) | 0 (0%) | |
| Number of ampullas with adenoma involvement: | ||||
| Yes | 20 (13.3%) | 15 (19%) | 5 (7%) | 0.0659 |
| No | 97 (64.7%) | 50 (63.3%) | 47 (66.2%) | |
| Missing | 33 (22%) | 14 (17.7%) | 19 (26.8%) | |
| Sum diameter duodenal polyps ≥10 mm | 65% (n = 97) | 82% (n = 67) | 44% (n = 30) | < 0.0001* |
| Number gastric polyps: | ||||
| Median (25th–75th percentile) | 72.5 (15–200) | 50 (15–150) | 100 (1–200) | 0.6703 |
| Patients with > 10 gastric polyps | 78.0% (117) | 81.0% (64) | 74.7% (53) | 0.3474 |
1Continuous variables compared with Wilcoxon rank sum test (number and sum diameter of polyps). Median and 25th–75th percentile describe the distribution of the variable within the Total, FAP and AFAP groups. Categorical values compared with chi-square test (sum diameter duodenal polyps > 10, patients > 10 gastric polyps).
*When smokers or recent NSAID usage was excluded, there was no change in significant associations with FAP vs AFAP